|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Daiichi Sankyo Co., Ltd., a global pharmaceutical company focused on cardiovascular, oncologic, metabolic, and infectious diseases. |
|---|---|
| Transferring Party | U3 Pharma AG, a German biotechnology company focusing on oncology. |
| Sector | Biopharmaceuticals |
| Date | May 21, 2008 |
| Analysis U3's pipeline includes fully human antibodies as potential therapies for breast, lung and colorectal cancer. The acquisition complements Daiichi's oncology portfolio, which currently has three human monoclonal antibodies in development. Deal value ~ $235m. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2010 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |